Introduction {#s1}
============

Osteoporosis (OP) and non-traumatic osteonecrosis (ON) are bone diseases affecting the quality of life. They are associated with low bone mass and increased fracture risk ([@B1], [@B2]). The prevalence of OP and ON is growing ([@B3]) and, although both diseases share some common risk factors (i.e., alcohol abuse and glucocorticoid treatment), their etiology is still not well-understood. It is now established that OP and ON are characterized by a decreased number of bone marrow mesenchymal stromal cells (MSC) and adipocyte accumulation in the bone marrow niche ([@B4]--[@B6]). Adipocytes release adipokines, cytokines and free fatty acids (FFA) that might influence skeletal cell survival and function and, hence, affect bone remodeling ([@B2], [@B7]--[@B9]).

FFA are an essential energy source for various cell types but it is recognized that a chronic exposure to high concentrations of those nutrients may be deleterious for cell function and survival in a process called lipotoxicity. The cellular and molecular mechanisms involved in lipotoxicity are still not completely understood although different processes have been described, including reactive oxygen species production ([@B10]), ceramide synthesis ([@B11]), and endoplasmic reticulum (ER) stress initiation ([@B12]). Lipotoxicity has been widely studied in different cell types including hepatocytes ([@B13]), pancreatic β cells ([@B14]), podocytes ([@B15]), and artery endothelial cells ([@B16]) but was poorly investigated in human MSC (hMSC). The role of lipotoxicity in the pathogenesis of bone diseases associated with lipid metabolism abnormalities such as OP and ON is now the subject of growing interest.

In a previous work, we showed that palmitic acid (Palm; C16:0), a saturated fatty acid (SFA), induced apoptosis of hMSC and osteoblasts. Cell death was preceded by activation of endoplasmic reticulum (ER) stress, pro-apoptotic pathways and by induction of a pro-inflammatory state. Addition of oleic acid (Ole; C18:1), a mono-unsaturated fatty acid (MUFA), prevented the deleterious effects of Palm by favoring its channeling and esterification in lipid droplets (LD) ([@B17]). We further demonstrated that SaOS-2 cells, a human osteoblastic cell line ([@B18]), co-treated with Palm and Ole accumulated higher intracellular amounts of Palm than SaOS-2 cells exposed to Palm alone ([@B17]). These observations led us to propose that the toxicity of the SFA is not correlated to its intracellular accumulation but, rather, could be related to the intracellular SFA/MUFA ratio ([@B17]).

In order to validate this hypothesis, we have now evaluated the implication of stearoyl-CoA 9-desaturase (SCD1) in hMSC protection against lipotoxicity. SCD1 catalyzes the desaturation of Palm and stearic acid (C18:0) in their monounsaturated counterparts, Cis-9-palmitoleic acid (C16:1) and Ole. Insulin, carbohydrates, SFA, MUFA, polyunsaturated fatty acids (PUFA) and cholesterol ([@B19], [@B20]) modulate expression of SCD1 by activation of different transcription factors such as liver X receptors (LXRs), peroxisome proliferator-activated receptors α, sterol regulatory element-binding proteins and CCAAT-enhancer-binding proteins (C/EBP)α.

LXRs are members of the nuclear hormone receptors superfamily of ligand-activated transcription factors inducing the expression of target genes after ligand binding. Oxysterol, oxidized cholesterol, cholesterol biosynthesis intermediates and glucose are natural ligands of LXRs and synthetic agonists of LXRs like T0901317 and GW3965 are routinely used for *in vitro* experiments ([@B16], [@B21]). LXR has two isoforms: LXRα that is mainly expressed in metabolically active tissues such as liver, intestine, macrophages, and adipose tissue and LXRβ which is ubiquitously expressed ([@B21], [@B22]).

In the present study, we postulate that LXRs activation could protect hMSC from lipotoxicity by modulating SCD1 expression and, consequently, inducing modifications of the intracellular SFA/MUFA ratio. Therefore, we examined the expression and regulation of the two isoforms of LXR in hMSC and we investigated the effect of a synthetic LXRs agonist, T0901317, on gene and protein expression as well as on cell function and survival.

Materials and Methods {#s2}
=====================

Isolation, Culture, and Characterization of hMSC
------------------------------------------------

hMSC were obtained from bone marrow aspirated from the posterior iliac crest of healthy volunteers and patient affected by osteonecrosis (all donors were aged ≥18 years). The study was approved by our local institutional ethical committee, Comité d\'Ethique hospitalo-facultaire Erasme-ULB (021/406), agreation number by "Ordre des Médecins" OM021. All participants gave their written consent. Bone marrow was diluted 1:0.5 with PBS and overlaid on Ficoll-Paque PREMIUM (GE Healthcare, Diegem, Belgium). Mononuclear cells were isolated after centrifugation and seeded at a density of 5.7 × 10^4^ cells/cm^2^ in DMEM low glucose (1 g/l; Invitrogen, Gent, Belgium) supplemented with 10% FBS (Sigma-Aldrich, Diegem, Belgium), 100 U/ml penicillin and 100 μg/ml streptomycin (Invitrogen, Gent, Belgium). The culture medium was renewed after 4 days of culture and then every 2--3 days until cells reached confluence. hMSC were detached by enzymatic treatment (Trypsin-EDTA; Invitrogen, Gent, Belgium) every week and seeded at a density of 5.7 × 10^3^ cells/cm^2^ until passage 8. In order to confirm the mesenchymal nature of the isolated cells, phenotyping by FACS flow cytometer and differentiation assays were performed ([@B17]). SaOS-2 cells, a human osteoblastic cell line (a kind gift from Bone Therapeutics, Gosselies, Belgium) were grown in McCoy\'s 5A medium (Invitrogen, Gent, Belgium) supplemented with 10% FBS, 100 U/ml penicillin and 100 μg/ml streptomycin. Culture conditions were the same as with hMSC.

Free Fatty Acid Treatment
-------------------------

Sodium oleate and sodium palmitate (Sigma-Aldrich Diegem, Belgium) were weighted and then solubilized in 90%/10% ethanol/water at 70°C to prepare 50 mM stock solutions. Before use, Palm and Ole were diluted in the appropriate culture medium (see below) containing 1% fatty acid free bovine serum albumin (BSA; Sigma-Aldrich, Diegem, Belgium). Taking into account the stepwise equilibrium model and the respective binding affinities of Palm and Ole for BSA ([@B23]) the free concentrations of palm and Ole used in our study are close to the physiological ones ([@B24]): it is estimated that in the presence of 0.5 mM total FA and 1% BSA, the free (i.e., unbound to BSA) Palm and Ole concentrations are, respectively, 27 nM and 47 nM ([@B25]). For FFA supplementation experiments, cells were cultured for the indicated times in a FA-specific medium composed of DMEM low glucose (hMSC) or McCoy\'s 5A (SaOS-2 cells) medium supplemented with 1% FBS, 100 U/ml penicillin, 100 μg/ml streptomycin, 1% FFA free BSA (Sigma-Aldrich, Diegem, Belgium) and, when required, diluted Palm and/or Ole (0.25--0.50 mM). As Palm and Ole were solved in ethanol, a similar dilution of the alcohol was added in the control culture condition (e.g., absence of FA).

T0901317 (N-(2,2,2-trifluoro-ethyl)-N-\[4-(2,2,2-tri-fluoro-1-hydroxy-1-trifluoromethyl-ethyl)-phenyl\]benzene-sulfonamide, Sigma-Aldrich Diegem, Belgium), the LXRs agonist, was solubilized in DMSO and used in pretreatment during 16 or 24 h and for treatment during 16, 24, or 48 h at 1--10,000 nM. CAY 10566 (CAY), the SCD1 inhibitor (3-\[4-(2-chloro-5-fluorophenoxy)-1-piperidinyl\]-6-(5-methyl-1,3,4-oxadiazol-2-yl)-pyridazine, Santa Cruz Biotechnology, Heidelberg, Germany) was dissolved in DMSO and used at 25 μM during 16, 24, or 48 h of treatment. Diluted DMSO was added in the control condition.

Determination of Cell Viability
-------------------------------

Cells were seeded in 96-well plates at a density of 14.7 × 10^3^ cells/cm^2^ for hMSC, and 20.6 × 10^3^ cells/cm^2^ for SaOS-2 cells. After 3 days, culture media were replaced by the FA-specific medium containing or not increasing concentrations of Palm and/or Ole for the indicated times and concentrations. At the end of the treatment period, the cells were washed and incubated for 15 min with the nuclear binding dyes propidium iodide 10 μg/ml (Sigma-Aldrich Diegem, Belgium) and Hoechst 33342 10 μg/ml (Sigma-Aldrich Diegem, Belgium). Cell viability was examined by inverted microscopy (Axiovision Zeiss, Zaventem, Belgium) with UV excitation (λ excitation/emission: 365/397 nm). Living cells were characterized by their intact nuclei with blue fluorescence, whereas dead cells were depicted by yellow-red fluorescence. In each experimental condition, a minimum of 500 cells were counted.

Measurement of Caspases-3/7 Activity
------------------------------------

Caspases-3/7 activity was determined using the Caspase-Glo® 3/7 assay (Promega, Leiden, The Netherlands). 29.4 × 10^3^ cells/cm^2^ were seeded in 96-well white plates. After 3 days, culture media were replaced by FA-specific medium supplemented with increasing concentrations of Palm, complemented or not with Ole, for the indicated times. At the end of the incubation period, 100 μl of culture medium were replaced by 100 μl of Caspase-Glo reagent resulting in cell lysis and cleavage of the Caspase-Glo® 3/7 substrate by the activated caspases. The luminescent signal generated was detected after 1 h using a Victor2 (PerkinElmer, Zaventem, Belgium).

Quantification of mRNA Expression by Quantitative Polymerase Chain Reaction (qPCR)
----------------------------------------------------------------------------------

Total RNA was isolated from cells seeded 3 days before treatment in 6-well plates at a density of 10.4 × 10^3^ cells/cm^2^, using AURUM^TM^ kit (Bio-Rad, Nazareth Eke, Belgium) according to the manufacturer\'s protocol. Total RNA (100 ng) was reverse transcribed in 20 μl using iScript cDNA synthesis kit (Bio-Rad, Nazareth Eke, Belgium). qPCR reactions were performed using a CFX96 thermal system (Bio-Rad, Nazareth Eke, Belgium) in a total reaction volume of 20 μl containing 3 mM MgCl~2~, 0.3 μM (each) forward and reverse primers ([Table 1](#T1){ref-type="table"}) (Eurogentec, Seraing, Belgium), 10 μl SYBR Green mix (Bio-Rad, Nazareth Eke, Belgium), and 2 μL cDNA. The cycling program was as follow: 95°C for 3 min followed by 40 cycles at 95°C for 30 s and 60°C for 30 sec. Hypoxanthine phosphoribosyltransferase 1 (*HPRT1*) was used as housekeeping gene.

###### 

Primer sequences for real-time PCR.

                       **Sequence**                       **Product size (bp)**
  -------------------- ---------------------------------- -----------------------
  *BiP (HSPA5*)-For    5′-ACCAATTATCAGCAAACTCTATGGAA-3′   74
  *BiP (HSPA5)-*Rev    5′-CATCTTTTTCTGCTGTATCCTCTTCA-3′   
  *CHOP (DDIT3)-*For   5′-TGGAAGCCTGGTATGAGGAC-3′         123
  *CHOP (DDIT3)-*Rev   5′-AAGCAGGGTCAAGAGTGGTG-3′         
  *HPRT1-*For          5′-GGCGTCGTGATTAGTGATGAT-3′        189
  *HPRT1-*Rev          5′-CTTGAGCACACAGAGGGCTAC-3′        
  *IL6-*For            5′-AGCCACTCACCTCTTCAGAACGAA-3′     122
  *IL6-*Rev            5′-CAGTGCCTCTTTGCTGCTTTCACA-3′     
  *IL8 (CXCL8)-*For    5′-GGACCACACTGCGCCAACACAG-3′       88
  *IL8 (CXCL8)-*Rev    5′-TCCACAACCCTCTGCACCCAGTT-3′      
  *LXRα (NR1H3)-*For   5′-CGCACTACATCTGCCACAGT-3′         141
  *LXRα (NR1H3)-*Rev   5′-TCAGGCGGATCTGTTCTTCT-3′         
  *LXRβ (NR1H2)-*For   5′-CCTCCTGAAGGCATCCACTA-3′         163
  *LXRβ (NR1H2)-*Rev   5′-GAACTCGAAGATGGGGTTGA-3′         
  *SCD1 (SCD)-*For     5′-TGTTCGTTGCCACTTTCTTG-3′         163
  *SCD1 (SCD)-*Rev     5′-TAGTTGTGGAAGCCCTCACC-3′         

Western Blotting
----------------

hMSC (10.4 × 10^3^ cells/cm^2^ in 6-well plates) were treated with FFA and then lyzed with Laemmli buffer (10% glycerol, 0.5 mM DTT, 63 mM Tris-HCl, 1% SDS, pH 6.8) containing a cocktail of proteases and phosphatases inhibitors (Roche Diagnostics, Vilvoorde, Belgium). Proteins were quantified by a paper dye binding assay. Equal protein amounts were separated by SDS-PAGE using 10% polyacrylamide gels. Proteins were transferred on polyvinylidene difluoride (PVDF) membranes Immobilion-P (Millipore, Overijse, Belgium) and immunolabeled overnight at 4°C using SCD1 antibody (rabbit, \#2438, lot 2, Cell Signaling Technology, Leiden, The Netherlands). Membranes were then incubated for 1 h at room temperature with the secondary antibody peroxidase-conjugated ECL^TM^ (GE healthcare, Diegem, Belgium). The immune complexes were detected by using the enhanced chemiluminescence method (Western Lightning® *Plus*-ECL, PerkinElmer Inc, Zaventem, Belgium). Band densities were quantified by ImageJ program (NIH, Bethesda, USA). Results were expressed as relative ratio between the protein of interest and β-actine (rabbit, \#4967, lot 7, Cell Signaling Technology, Leiden, The Netherlands).

Detection of Intracellular Lipid Droplets
-----------------------------------------

SaOS-2 cells were seeded in 6 well plates at 20.6 × 10^3^ cells/cm^2^. When required, cells were pretreated with T0901317 (10 μM) during 16 h. After 24 h incubation in the presence or absence of Palm (0.25 mM), T0901317 (10 μM) and/or CAY (25 μM), SaOS-2 cells were washed twice with PBS and fixed with 4% paraformaldehyde for 15 min. The neutral lipids accumulated in intracellular LD were stained by BODIPY™ 493/503 (D3922, Thermofisher, Alost, Belgium) 1 μg/ml for 1 h. Nuclei were stained by Hoechst 33342 10 μg/ml (Sigma-Aldrich, Diegem, Belgium) for 10 min. After coloration, cells were rinsed twice with PBS before microscopic observation, in DMEM without FBS at room temperature using an Axiovert 200M fluorescence microscope and Axiocam MRm (Axiovision Zeiss, Zaventem, Belgium). The images have been merged with Axiovision software and scales have been added with ImageJ program (NIH, Bethesda, USA).

Ultrastructural Analysis by Electron Microscopy (EM)
----------------------------------------------------

SaOS-2 cells were seeded in flask of 75 cm^2^ at a density of 20.6 × 10^3^ cells/cm^2^. Cells were pretreated with or without T0901317 (10 μM) during 16 h and further cultured in control conditions or treated for 24 h with Palm (0.25 mM), T0901317 (10 μM) and/or CAY 10566 (CAY) (25 μM). Cells were then collected and centrifuged at 320 g and the pellets were fixed with 4% (v/v) glutaraldehyde in 0.1 mol/L phosphate buffer (Millonig\'s buffer) at pH 7.4 for 1 h at RT. After 24 h washing in Millonig\'s buffer containing 0.5% sucrose (w/v), cells were post-fixed in 2% (w/v) OsO4 for 45 min, dehydrated, and embedded in Epon. Ultrathin sections were counterstained with lead citrate and uranyl acetate and observed with a Zeiss EM 109 at 50 kV ([@B26]). Scales have been added on images with ImageJ program (NIH, Bethesda, USA).

Gas Chromatography Analysis
---------------------------

SaOS-2 cells were seeded in flasks of 75 cm^2^ at a density of 20.6 × 10^3^ cells/cm^2^,and pretreated with or without T0901317 (10 μM) during 16 h. To evaluate the cellular content of FA after 24 h of treatment in the presence or absence of Palm (0.25 mM), T0901317 (10 μM), and/or CAY (25 μM), cells were washed with PBS, scrapped and collected in 1 ml lysis buffer (1% SDS, 60 mM Tris-HCl and 10 mM EDTA). Total lipids were extracted with chloroform/methanol/water (2:2:1) and separated on a solid phase extraction -columns (Bond Elut-NH2, 200 mg, 3 ml, Agilent, Diegem, Belgium) in 3 fractions: free FA, neutral lipids (e.g., mono-, di- and triglycerides and cholesterol esters) and phospholipids. Quantification and characterization of the FA profile of the 3 lipidic fractions were then performed according to Louis et al. ([@B27]) on a Agilent 6890 series gas chromatography with a Supelco 24019 column (Sigma-Aldrich, Diegem, Belgium).

Statistical Analysis
--------------------

Data are presented as means ± SEM. Values were determined from at least three independent experiments. Statistical analysis was performed by SPSS using Student\'s *t*-test or one-way ANOVA followed by *t*-test with the Fisher LSD correction for triple comparisons. Differences between groups were considered as statistically significant at *p* \< 0.05.

Results {#s3}
=======

LXRs Activation Triggers LXRα Expression in hMSC
------------------------------------------------

T0901317 is a non-steroidal agonist of both isoforms of the transcription factor LXR, inducing the expression of genes under their control ([@B28]). To study the effect of LXRs activation, hMSC were pretreated during 16 h with T0901317 (1 nM to 10 μM) before a further 24 h culture period in the absence or presence of 0,25 mM of Palm or Ole.

As previously described in other cell types, T0901317 increased *LXR*α mRNA in a dose-dependent manner in hMSC but neither Palm, nor Ole significantly affected *LXR*α expression ([Figure 1A](#F1){ref-type="fig"}). Neither T0901317, nor Ole (0.25 mM), nor Palm (0.25 mM) modulated the expression of LXRβ, the FFA being tested individually or in combination ([Figure 1B](#F1){ref-type="fig"}).

![T0901317 increases the expression of LXRα. hMSC were pretreated during 16 h with T0901317 and treated for 24 h with T0901317 in the absence of Palm (white column) or in the presence of Palm 0.25 mM (gray column), Ole 0.25 mM (shaded column). LXRα **(A)**, LXRβ **(B)**, expression were quantified by qPCR using the ΔΔCT method. Values were normalized for HPRT1 expression and are expressed as the ΔΔCT relative to control (Ctrl). Results are mean ± SEM of 9-12 individual experiments. ^\*^*p* \< 0.01; ^\*\*^*p* \< 0.001 vs. Ctrl; ^*\#\#*^*p* \< 0.001 vs. Palm 0.25 mM.](fendo-10-00726-g0001){#F1}

LXRs Activation Protects hMSC From Palm Cytotoxicity and Represses Palm-Induced ER Stress and Inflammation
----------------------------------------------------------------------------------------------------------

As shown before ([@B17]), treatment of hMSC with Palm (0.25 mM or 0.50 mM) induced cell death and activated caspases 3/7 ([Figures 2A,B](#F2){ref-type="fig"}). We now demonstrated that addition of T0901317 decreased Palm-triggered cell mortality in a dose-dependent manner. At the highest concentration tested (100 nM), T0901317 abolished cell death and caspases 3/7 activation ([Figures 2A,B](#F2){ref-type="fig"}). T0901317 did not significantly affect cell viability and caspase 3/7 activation ([Supplementary Figure 1A](#SM1){ref-type="supplementary-material"}).

![T0901317 decreases Palm-induced cell death. hMSC were pretreated during 16 h with T0901317 and treated 24 h with T0901317 in the absence of Palm (white column) or in the presence of Palm 0.25 mM (gray column) or 0.50 mM (black column). Cell death **(A)** was quantified by nuclear staining with Hoechst and propidium iodide. Values are mean ± SEM of 12--17 individual experiments. Caspases-3/7 activity **(B)** was measured using the Caspases-3/7 Glo assay. Values are expressed relative to Ctrl and are mean ± SEM of 3 individual experiments. ^\*^*p* \< 0.05; vs. Ctrl; ^\*\*^*p* \< 0.001; ^\#^*p* \< 0.05; ^*\#\#*^\< 0.001 vs. Palm 0.25 mM; ^μ^*p* \< 0.05; ^μμ^ \<0.001 vs. Palm 0.50 mM.](fendo-10-00726-g0002){#F2}

Ig heavy-chain binding protein (BiP) and C/EBP homologous protein (CHOP) are usually used as ER stress markers. We confirmed that cell treatment with Palm increased *BiP* and *CHOP* mRNA ([Figures 3A,B](#F3){ref-type="fig"}) as well as the expression of the pro-inflammatory cytokines *IL6* and *IL8* ([Figures 3C,D](#F3){ref-type="fig"}). Furthermore, our results revealed that LXRs activation by T0901317 decreased Palm-induced gene expression related to ER stress and cytokines in a dose-dependent manner in hMSC.

![T0901317 counteracts Palm-induced ER stress and inflammation in a dose dependent manner. hMSC were pretreated during 16 h with T0901317 and treated for 24 h with T0901317 in the absence (white column), or in the presence of Palm 0.25 mM (gray column). BiP **(A)** and CHOP **(C)** was used as marker of ER stress. IL6 **(B)**, IL8 **(D)** was used to showed inflammation. Gene expression was quantified by qPCR using the ΔΔCT method. Values were normalized for HPRT1 expression and are expressed as the ΔΔCT compared to control (Ctrl). Results are mean ± SEM of 12 individual experiments. ^\*^*p* \< 0.05; ^\*\*^*p* \< 0.01; ^\*\*\*^*p* \< 0.001 vs. Ctrl; ^\#^*p* \< 0.05; ^*\#\#*^*p* \< 0.01 ^*\#\#\#*^*p* \< 0.001 vs. Palm 0.25 mM.](fendo-10-00726-g0003){#F3}

LXRs Activation Increases SCD1 Expression in hMSC
-------------------------------------------------

SCD1 is an enzyme implicated in FFA metabolism by converting SFA into MUFA. Its expression is under the control of several factors including LXRs ([@B20]). We observed that T0901317, a LXRs agonist, significantly increased SCD1 expression in a dose-dependent manner at both mRNA and protein levels in hMSC ([Figures 4A,B](#F4){ref-type="fig"}). Palm used alone or in combination with T0901317, did not significantly regulate SCD1 protein expression. Of interest, we observed that Ole, tested alone or in combination with Palm, significantly decreased *SCD1* mRNA ([Figure 4A](#F4){ref-type="fig"}).

![T0901317 increases SCD1 mRNA and protein expression. hMSC were pretreated during 16 h with T0901317 and treated for 24 h with T0901317 in the absence (white column), or presence of Palm 0.25 mM (gray column), Ole 0.25 mM (shaded column). SCD1 mRNA expression **(A)**, was quantified by qPCR using the ΔΔCT method. Values were normalized for HPRT1 expression and are expressed as the ΔΔCT compared to control (Ctrl). Values are mean ± SEM of 12 individual experiments SCD1 protein level **(B)**, was evaluated by Western blotting and normalized for β actine and Ctrl. Values are mean ± SEM of 7 individual experiments. ^\*^*p* \< 0.05; ^\*\*^*p* \< 0.01; ^\*\*\*^*p* \< 0.001 vs. Ctrl; ^\#^*p* \< 0.05; ^*\#\#*^*p* \< 0.01 ^*\#\#\#*^*p* \< 0.001 vs. Palm 0.25 mM.](fendo-10-00726-g0004){#F4}

Inhibition of SCD1 Activity Abolishes the Protective Action of the LXRs Agonist in hMSC
---------------------------------------------------------------------------------------

CAY 10566 (CAY) is a potent and selective inhibitor of SCD1 activity, thus preventing the conversion of SFA into MUFA ([@B29]). CAY did not significantly affected cell death or caspase activity ([Supplementary Figure 1B](#SM1){ref-type="supplementary-material"}). In the presence of Palm 0.25 mM, inhibition of SCD1 by CAY significantly magnified the toxicity of the SFA, increasing both cell death and caspases 3/7 activation. Furthermore, our results demonstrated that inhibition of SCD1 activity abolished the protective action of the LXRs agonist T0901317 on Palm-triggered cell death and caspases 3/7 activation ([Figure 5](#F5){ref-type="fig"}).

![CAY suppresses T0901317 effect on cell viability and caspases 3/7 activation. hMSC were pretreated during 16 h with T0901317 and treated 48 h with T0901317, CAY 25 μM in the absence (white column) or presence of Palm 0.25 mM (gray column). Cell death **(A)** was quantified by nuclear staining with Hoechst and propidium iodide. Values are mean ± SEM of 4 individual experiments. Caspases-3/7 activity **(B)** was measured using the Caspases-3/7 Glo assay. Values are expressed relative to Ctrl and are mean ± SEM of 3 individual experiments. ^\*^*p* \< 0.05; ^\*\*^*p* \< 0.01 vs. Ctrl; ^\#^*p* \< 0.05; ^*\#\#*^*p*\< 0.01 vs. Palm 0.25 mM; ^*\$*^*p* \< 0.05; ^*\$\$*^*p* \< 0.01 vs. Palm 0.25 mM + T0901317 100 nM.](fendo-10-00726-g0005){#F5}

Activation of LXRs Increases FFA Incorporation in Lipid Droplets in SaOS-2 Cells
--------------------------------------------------------------------------------

We further evaluated the impact of LXRs activation and SCD1 inhibition on ER morphology in Palm-treated cells. Cell imaging by EM and FA quantification and analysis require large amounts of biological material. As hMSC are a rare and precious resource, SaOS-2 cells, a human osteoblastic cell line, were used to perform EM as we previously demonstrated that those cells are highly sensitive to lipotoxicity, showing a greater decrease of cell viability and a stronger activation of caspases 3/7 and ER stress in response to Palm than hMSC and hMSC-derived osteoblasts ([@B17]). The present results documented that LXRs activation increased SCD1 expression and viability in SaOS-2 cells ([Supplementary Figures 2A,B](#SM1){ref-type="supplementary-material"}), as observed in hMSC ([Figures 2A](#F2){ref-type="fig"}, [4A](#F4){ref-type="fig"}).

Lipid droplets (LD) were not detected in SaOS-2 cells cultured in control condition ([Figures 6A,E](#F6){ref-type="fig"}), whereas, as shown in [Figure 6B](#F6){ref-type="fig"}, Palm-treated SaOS-2 cells displayed bodipy signal and we observed by EM that the ER was disrupted and inflated or angular ([Figure 6F](#F6){ref-type="fig"}). Bodipy fluorescence markedly increased in SaOS-2 cells co-treated with Palm and T0901317 (10 μM) ([Figure 6C](#F6){ref-type="fig"}). Moreover, we noticed the presence of numerous large LD surrounding the nucleus and often located in contact with, or close to, mitochondria ([Figure 6G](#F6){ref-type="fig"}); the ER structure appeared unaltered in most of the cells. Addition of CAY, the SCD1 inhibitor, to Palm and T0901317 suppressed LD formation, severely damaged the ER ([Figures 6D--H](#F6){ref-type="fig"}) and induced cell death ([Supplementaury Figure 2B](#SM1){ref-type="supplementary-material"}).

![T0901317 induces LD formation in the presence of Palm and counteracts Palm-induced ER disturbance. SaOS-2 cells were pretreated during 24 h with 10 μM T0901317 (T0) and treated for 16 h with T0901317 10 μM, CAY 25 μM in absence, or in the presence of Palm 0.25 mM. Bodipy staining of lipidic vacuoles, microscopic observations were performed with a 20 fold magnification lenses **(A--D)**. Electron micrographs **(E--H)**. Arrow, inflated ER; discontinued arrow, angular ER; LD, lipid droplet; M, mitochondria.](fendo-10-00726-g0006){#F6}

LXRs Activation Abolishes Palm-Induced Modifications of the SFA/MUFA Ratio in SaOS-2 Cells
------------------------------------------------------------------------------------------

We further characterized and quantified the fatty acids (FA) present in the FFA, neutral lipids (NL) and phospholipids (PL) fractions obtained from SaOS-2 cell lysates cultured in control conditions or in the presence of Palm, Palm and T0901317, and/or CAY. The FA profile (i.e., SFA, MUFA, and PUFA contents) of the FFA fraction was unaffected by the different culture conditions (data not shown).

When cells were exposed to Palm, we observed an important accumulation of SFA in the NL fraction whereas the MUFA content was slightly decreased ([Figure 7A](#F7){ref-type="fig"}). Of note, myristic acid (C14:0) augmented but its total amount remained smaller than Palm ([Table 2](#T2){ref-type="table"}). Taken together, these modifications led to an increase of the SFA/MUFA ratio from 4 to 11 in SaOS-2 cells exposed to Palm.

![Relative FA content in SFA and MUFA. Normalized FA composition of SaOS-2 cells extract regroup in 2 classes: SFA and MUFA. Values are expressed relative to Ctrl. SaOS-2 cells were pretreated during 24 h with T0901317 and treated 16 h with T0901317 10 μM, CAY 25 μM in absence, or in the presence of Palm 0.25 mM. The fat extract is separated in 3 fractions: NL **(A)**, PL **(B)** and FFA (data not shown). Values are mean ± SEM from 4 to 7 individual experiments.](fendo-10-00726-g0007){#F7}

###### 

Modifications of SFA and MUFA content in SaOs-2 cells treated with Palm, an agonist of LXRs and/or a SCD1 inhibitor.

  **Fatty acid**       **Ctrl**                   **Palm 0.25 mM**                                                **Palm 0.25 mM + T0901317 10 μM**                                **Palm 0.25 mM + T0901317 10 μM + CAY 25 μM**
  -------------------- -------------------------- --------------------------------------------------------------- ---------------------------------------------------------------- ---------------------------------------------------------------
  **NEUTRAL LIPIDS**                                                                                                                                                               
  C14:0                0.05 ± 0.03                0.30 ± 0.12                                                     1.89 ± 0.31[^\#\#^](#TN5){ref-type="table-fn"}                   0.85 ± 0.20[^\$\$\$^](#TN9){ref-type="table-fn"}
  C16:0                3.59 ± 0.11                14.66 ± 0.61[^\*\*^](#TN2){ref-type="table-fn"}                 76.13 ± 9.95[^\#\#\#^](#TN6){ref-type="table-fn"}                39.87 ± 5.91[^\$\$\$^](#TN9){ref-type="table-fn"}
  C18:0                5.04 ± 0.30                5.63 ± 0.38                                                     7.69 ± 0.62                                                      8.36 ± 0.89
  **Total SFA**        **8.67** **±** **0.38**    **20.58** **±** **0.58[^\*\*\*^](#TN3){ref-type="table-fn"}**   **85.99** **±** **10.83**[^\#\#\#^](#TN6){ref-type="table-fn"}   **49.08** **±** **6.51[^\$\$\$^](#TN9){ref-type="table-fn"}**
  C16:1cis9            ND                         0.30 ± 0.11[^\*^](#TN1){ref-type="table-fn"}                    7.81 ± 1.07[^\#\#\#^](#TN6){ref-type="table-fn"}                 0.28 ± 0.11[^\$\$\$^](#TN9){ref-type="table-fn"}
  C18:1cis9            1.08 ± 0.27                1.18 ± 0.07                                                     5.30 ± 0.85[^\#\#^](#TN5){ref-type="table-fn"}                   1.58 ± 0.22[^\$\$^](#TN8){ref-type="table-fn"}
  C18:1cis11           1.09 ± 0.41                0.44 ± 0.28                                                     5.67 ± 0.83[^\#\#\#^](#TN6){ref-type="table-fn"}                 0.95 ± 0.48[^\$\$\$^](#TN9){ref-type="table-fn"}
  **Total MUFA**       **2.17** **±** **0.61**    **1.93** **±** **0.37**                                         **19.09** **±** **2.75**[^\#\#\#^](#TN6){ref-type="table-fn"}    **2.84** **±** **0.72[^\$\$\$^](#TN9){ref-type="table-fn"}**
  **PHOSPHOLIPIDS**                                                                                                                                                                
  C14:0                0.91 ± 0.21                0.56 ± 0.18[^\*^](#TN1){ref-type="table-fn"}                    0.40 ± 0.16[^\#^](#TN4){ref-type="table-fn"}                     1.07 ± 0.32[^\$^](#TN7){ref-type="table-fn"}
  C16:0                17.04 ± 2.55               20.08 ± 4.01                                                    19.85 ± 3.90                                                     36.11 ± 7.89[^\$^](#TN7){ref-type="table-fn"}
  C18:0                5.90 ± 0.77                5.38 ± 0.71                                                     5.99 ± 0.88                                                      7.68 ± 1.56
  **Total SFA**        **23.85** **±** **3.37**   **26.02** **±** **4.86**                                        **26.24** **±** **4.85[^\#^](#TN4){ref-type="table-fn"}**        **44.86** **±** **9.67[^\$^](#TN7){ref-type="table-fn"}**
  C16:1cis9            0.71 ± 0.09                1.10 ± 0.19                                                     2.06 ± 0.46[^\#^](#TN4){ref-type="table-fn"}                     0.12 ± 0.12[^\$^](#TN7){ref-type="table-fn"}
  C18:1cis9            4.86 ± 0.66                3.06 ± 0.47[^\*^](#TN1){ref-type="table-fn"}                    3.42 ± 0.62                                                      1.29 ± 0.66^S^
  C18:1cis11           2.52 ± 0.30                1.42 ± 0.19[^\*^](#TN1){ref-type="table-fn"}                    1.85 ± 0.30                                                      0.62 ± 0.38[^\$^](#TN7){ref-type="table-fn"}
  **Total MUFA**       **8.20** **±** **1.07**    **5.66** **±** **0.88**                                         **7.40** **±** **1.41[^\#^](#TN4){ref-type="table-fn"}**         **2.05** **±** **1.13[^\$^](#TN7){ref-type="table-fn"}**

*Main FA extracted in SaOS-2 cells. SaOS-2 cells were pretreated during 24 h with T0901317 and treated 16 h with Palm 0.25 mM in the presence or absence of T0901317 10 μM and CAY 25 μM. Values are mean ± SEM of 4--7 individual experiments and are expressed in ng of fatty acid per μg of cell protein*.

p \<0.05;

p \<0.01 vs. Ctrl;

p \<0.001;

p \<0.05;

p \<0.01;

p \<0.001 vs. Palm 0.25 mM;

p \<0.05;

p \<0.01;

*p \<0.001 vs. Palm 0.25 mM + T0901317 100 nM*.

As shown in [Table 2](#T2){ref-type="table"}, activation of LXRs by T0901317 in the presence of Palm induced a massive cellular accumulation of NL (10 times the amount measured in the control condition). As both SFA (from 9 to 86 ng/μg cell protein) and MUFA (from 2 to 19 ng/μg cell protein) increased, LXRs activation restored the SFA/MUFA ratio close to its control value ([Figure 7A](#F7){ref-type="fig"}). Of note, Palm represented 65% of the total SFA.

In Palm + T0901317 treated cells, inhibition of SCD1 by CAY decreased twice the NL fraction, as compared to Palm + T0901317 treated cells. As total SFA and MUFA were decreased by 40 and 85%, respectively, the SFA/MUFA ratio increased to 17.3, principally due to modifications of Palm and of Cis-9-palmitoleic acid, Ole and Cis-11-vaccenic acid contents ([Table 2](#T2){ref-type="table"}).

In the PL fraction ([Figure 7B](#F7){ref-type="fig"}), Palm or Palm + T0901317 treatments did not significantly affect SFA and MUFA content. However, addition of CAY to Palm and T0901317 doubled the SFA content while decreasing 4 times the quantity of MUFA. The SFA/MUFA ratio was thus only significantly affected by the concomitant presence of Palm, T0901317 and CAY in the PL fraction. Of note, despite the fact that we observed that the total lipid content was not significantly modified by Palm, the SFA/MUFA ratio was enhanced by around 50% as Palm content increased while Ole and Cis-11-vaccenic acid amounts decreased ([Figure 7B](#F7){ref-type="fig"}, [Table 2](#T2){ref-type="table"}). Conversely, addition of T0901317 to Palm reduced the SFA/MUFA ratio, although in a non-significant manner, compared to Palm alone treatment ([Figure 7B](#F7){ref-type="fig"}).

Of note, as expected, in both the NL and PL fractions, Palm slightly raised the quantity of Cis-9-palmitoleic acid whereas addition of T0901317 largely increased it ([Table 2](#T2){ref-type="table"}).

The objective of the present work is to evaluate the hypothesis that Palm lipotoxicity is prevented by decreasing the SFA/MUFA ratio in hMSC. To reach this purpose, cells were treated with a LXRs agonist in order to trigger SCD1 expression. SCD1 is an enzyme located in the ER membrane where it catalyzes the desaturation of SFA in their monounsaturated counterparts; its expression is upregulated by nutrients such as glucose, fructose, SFA and by LXR activation ([@B30]). Due to the very short half-life (3--4 h) of SCD1 protein, the activity of the enzyme is easily controlled via regulation of its expression ([@B31]).

Discussion {#s4}
==========

LXRs are mainly known for their regulatory function on lipid and carbohydrate metabolism by oxysterols, the main natural LXRs ligands ([@B32], [@B33]). Indeed, LXRs regulate expression of genes involved in cholesterol metabolism and efflux. In the liver, LXRs induce the expression of several enzymes, including SCD1 ([@B34]). Oxysterols were implicated in osteoblastic and adipogenic differentiation of murine MSC, although their influence is still under debate. In mouse bone marrow-derived MSC, it was reported that activation of LXRs inhibits sonic hedgehog-induced osteoblastic differentiation ([@B35]). At the opposite, oxysterols were shown to promote osteoblastic differentiation by activation of both the hedgehog ([@B36]) and the LXRs signaling pathways ([@B37]) while they reduce adipogenic differentiation in a mouse multipotent bone marrow stromal cell line ([@B36]). Moreover, it was documented that oxysterol 20(S)-Hydroxycholesterol stimulates osteogenic differentiation by inducing notch target gene expression ([@B37]). Interestingly the overexpression of LXRα has an inhibitory effect on adipocyte differentiation ([@B38]), and LXRs activation was shown to decrease osteoclastogenesis and to trigger osteoclast apoptosis ([@B39]), thus reducing *in vitro* bone resorption ([@B40]). In a co-culture osteoporosis model of mouse osteoblasts and osteoclasts, LXRs activation counteracts osteoclastogenesis via inhibition of receptor activator of nuclear factor kappa-B ligand (RANKL) production by osteoblasts. In this model, activation of LXRs restores a physiological RANKL/osteoprotegerin ratio, promoting bone homeostasis ([@B41]). Up to now, the impact of LXRs activation on the biology of human MSC has been poorly investigated. In a particular cell sub-population, the multilineage-differentiating stress enduring (Muse) cells, LXRs activation has been linked to stem cell self-renewal and immunomodulation ([@B42]). The presence of LXRs-responsive elements in the LXRα promoter was previously documented, allowing regulation of LXRα expression by its own ligand in different cell types ([@B43]). In the present study, we confirm that hMSC expressed both LXR isoforms and we demonstrate that LXRs activation increases LXRα expression \[the isoform particularly implicated in the control of lipid biosynthesis ([@B22])\] without affecting LXRβ expression. We further reveal for the first time that LXRs activation totally counteracts the deleterious effects of Palm in hMSC. LXRs were recently described as a connection between lipid metabolism and immune response ([@B44]). Indeed, in macrophages, LXRs activation counteracts the effects of LPS on expression of cytokines such as IL6 and IL1β and of the chemokine monocyte chemoattractant protein-1 (MCP-1), probably through modulation of NF-kB activity ([@B45]). In hMSC, our results show that LXRs activation decreases the inflammatory process triggered by Palm as IL6 and IL8 expression are significantly reduced. These observations are in line with the results of Wang et al. who demonstrated that activation of LXRs by artificial ligand decreases inflammation via toll-like receptor 4 (TLR4)/NF-κB and Keap-1/Nrf-2 pathways in adipose-derived mouse MSC ([@B46]). In macrophages, TLR4 activation reduces LXRs activation and decreases LXRs target gene expression after bacterial infection ([@B47]), suggesting a crosstalk between the two signaling pathways. Of interest, SFA are endogenous ligands of TLR4 and we have previously showed that Palm activates NF-kB and increases TLR4 expression as well as IL6 and IL8 secretion in hMSC, suggesting that TLR pathway might be embroiled in Palm-induced lipotoxicity in hMSC ([@B17]).

LXRs agonists such as SFA are known to upregulate SCD1 expression while MUFA and PUFA decrease SCD1 transcription in human aortic smooth muscle cells and mouse hepatocytes ([@B30], [@B31]). In the present work, we demonstrate for the first time a dose dependent effect of T0901317, the LXRs agonist on both SCD1 mRNA and protein expression in hMSC. As expected, Ole decreases SCD1 transcription. However, we could not show a significant effect of Palm on SCD1 mRNA and protein expression but this could be related to the high variability of SCD1 expression between subjects ([Supplementary Figure 3](#SM1){ref-type="supplementary-material"}), as previously documented ([@B48]). Our observations are in fair agreement with the literature as Karaskov et al., showed that medium-chain SFA, and particularly lauric acid (C12:0), bind and activate LXRα whereas long-chain SFA have no effect ([@B49]). Moreover, Bedi et al. observed that Palm binds to but does not activate LXRα in LXRα-transfected COS-7 cells ([@B50]).

The molecular mechanisms involved in SFA-induced lipotoxicity are still not fully understood. Various mechanisms were described ([@B10]--[@B12]), some are common to all cell types while others are specific of the cell type examined. SFA may provoke cell death by induction of an ER stress as Palm accumulation in the ER induces its engorgement, leading to disruption of the ER homeostasis and activation of the unfolded protein response (UPR) ([@B51]). UPR initially acts as a pro-survival response by triggering distinct mechanisms to overcome the ER overload: decreased protein translation, increased ER chaperone synthesis and misfolded protein clearance. If UPR does not successfully manage the ER engorgement, the response switches to activation of a pro-apoptotic pathway and, finally, leads to cell death ([@B13], [@B41]). In hMSC, we previously demonstrated that Palm treatment activates UPR by increasing expression of BiP, an ER chaperone and CHOP, an UPR-related protein inducing cell death. Activation of UPR is concomitant with caspases 3/7 activation and cell death ([@B17]). We now demonstrate that the LXRs agonist T090137 counteracts Palm activation of the UPR pathway and of caspases 3/7, thus promoting hMSC survival. All these effects are likely mediated by activation of SCD1 expression since inhibition of SCD1 activity abrogates the beneficial impacts of T090137.

In INS-1E cells, a rat pancreatic β cell line, downregulation of SCD1 expression enhances ER stress and apoptosis ([@B52]) whereas increasing SCD1 expression prevents lipotoxicity by favoring the incorporation of Palm in LD ([@B53]) These observations are in line with the present work, as we showed that the LXRs agonist T0901317 triggers SCD1 expression, LD formation and protects hMSC from Palm-induced toxicity. To further characterize the effects of Palm on cell organelles by EM, we used SaOS-2 cells, a human osteoblastic cell line, as susceptible to lipotoxicity than hMSC and hMSC-derived osteoblasts ([@B17]). Our results establish that Palm treatment distends the ER and induces ER membrane rupture. SaOS-2 cells co-treated with Palm and the LXRs agonist display LD formation and present less ER abnormalities such as inflated, angular or disrupted ER and cell viability is preserved. Lastly, we show that addition of an inhibitor of SCD1 activity to Palm and T0901317 suppress LD formation, provokes substantial damage to the whole cytoplasm and magnifies cell death, demonstrating the key role of SCD1 in the anti-lipotoxicity action of the LXRs agonist.

To further characterize the molecular mechanisms involved in the beneficial action of LXRs activation, we used gas chromatography to determinate the changes in nature and amount of the FA constituting LD and membrane in cells cultured in our different experimental conditions. Cell lipid extracts were separated into three fractions: (1) neutral lipids (NL) that are essentially composed of triglycerides, (2) phospholipids (PL), containing the membrane phospholipids, and (3) FFA, the non-esterified fatty acids. We observed that the lipid composition of this last fraction is unaffected by the different treatments tested (data not shown), as previously stated by Ariyama et al. in Hela cells ([@B54]).

In the NL fraction, Palm treatment increases the total lipid amount as well as the SFA/MUFA ratio, which is linked to enhanced cell death. Addition of the LXRs agonist to Palm drastically augments the total amount of NL, particularly the MUFA part, resulting in a decreased SFA/MUFA ratio that is associated with enhanced LD formation, as identified by EM. Upregulation of SCD1 protein synthesis by LXRs activation protects cells from lipotoxicity probably by promoting conversion of Palm to palmitoleic acid and, therefore, favoring its further integration in triglycerides and storage in LD. Indeed, it is known that MUFA are more easily added to diacylglycerol than SFA by the triglyceride-forming enzyme diacylglycerol O-acyltransferase ([@B55]). Inhibition of SCD1 activity drastically decreases the MUFA content, leading to a rise of the SFA/MUFA ratio and increased cell mortality. Altogether, these results corroborate the hypothesis that the beneficial action of the LXRs agonist is mediated by SCD1 increased expression and activity. As ER stress is also induced by alteration of the ER membrane fluidity ([@B14], [@B54], [@B56]), we hypothesized that in Palm-treated hMSC, an increase of saturated PL content could favor stiffening of the membranes and, therefore, participate to ER stress and cell mortality. Indeed, Chamulitrat et al. observed a 2.12 fold increase of the SFA/MUFA ratio in PL concomitant to caspases 3/7 activation when mouse hepatocytes are treated with Palm ([@B56]). In our work, even if Palm treatment has no significant effect on the SFA/MUFA ratio in the PL fraction, we observe nevertheless a 1.59 fold increase. Such a rise is weak but was reproducible; improving the experimental protocol by purification of ER membranes could probably permit to reach significant statistical results but this would require a huge number of cells to be performed. Furthermore, our results are concordant with literature and with our EM observations, supporting the idea that the degree of saturation of PL is embroiled in ER stress and cell death ([@B14], [@B56]).

Modifications of the PL membrane SFA/MUFA ratio affects membrane properties by several mechanisms and a membrane enriched in saturated PL shows perturbation of protein activity. Li et al. demonstrated on RAW 264.7 macrophages that saturated PL inhibit the activity of the sarco(endo)plasmic reticulum calcium ATPase-2b (SERCA2b), a calcium pump ([@B57]), leading to ER Ca^2+^ depletion and ER stress. In addition, increasing PL membrane saturation triggers the recruitment of cellular Src kinase to the membrane, activates c-Jun N-terminal kinases (JNK) signaling pathway and so, potentially induces inflammation ([@B58]). In hMSC, Palm causes inflammation but we have not observed modifications of JNK phosphorylation (data not shown). Palm may also affect membrane properties simply by modifying its hydrophobic nature as Palm aggregates within the membranes and thus increases membrane permeability ([@B59]). While addition of the LXRs agonist to Palm abolishes cell death, we have only observed a weak decrease of the SFA/MUFA ratio in the PL fraction ([Figure 7B](#F7){ref-type="fig"}), mainly due to a significant rise (\>25 fold) of Cis-9-palmitoleic acid ([Table 2](#T2){ref-type="table"}). In hMSC, such an increase could indeed partially restore membrane fluidity and thus contributes to preservation of cell viability, as mentioned in the literature ([@B60]).

Taken as a whole, our results suggest that lipotoxicity is not related to the accumulation of intracellular Palm but rather to the SFA/MUFA ratio in NL and PL fractions. Indeed, hMSC co-treated with Palm and the LXRs agonist have the largest amount of Palm in the NL fraction, a SFA/MUFA ratio similar to the control condition and do not suffer from lipotoxicity. In contrast, cells treated with Palm alone or in combination with the LXR agonist and the inhibitor of SCD1 contain less Palm in the NL fraction, present a high SFA/MUFA ratio and increased cell death.

ON and OP are bone diseases sharing common similarities such as bone marrow adipocyte accumulation as well as blood increase in triglycerides, high density lipoprotein (HDL) and cholesterol concentrations ([@B61], [@B62]). In a previous work, we have demonstrated that the bone marrow microenvironment of ON patients is enriched in SFA when compared to healthy subjects ([@B9]). Moreover, hMSC isolated from ON patients (ON~MSC~) are more sensitive to lipotoxicity than hMSC obtained from healthy volunteers (HV~MSC~). These observations were associated with an inverse regulation of SCD1 expression by Palm: Palm triggered SCD1 expression in HV~MSC~ whereas it reduced it in ON~MSC~ ([@B9]). Moreover, the basal expression level of carnitine palmitoyltransferase I, the limiting enzyme of FA β-oxidation, was 2 fold lower in ON~MSC~ than in HV~MSC~, indicating that lipid degradation is also affected in ON~MSC~ ([@B9]). Of note, dysfunctions of the NF-kB, TLR and TNF pathways implicating LXRs were recently highlighted in ON and OP patients ([@B44], [@B63], [@B64]). Altogether our observations suggest an important role for SCD1 in the prevention of lipotoxicity in hMSC.

Of note, dysfunctions of the NF-kB, TLR and TNF pathways implicating LXRs were recently highlighted in ON and OP patients ([@B44], [@B63], [@B64]).

In animal models, LXRs agonists are tested to treat hyperlipidemia ([@B65]) and atherosclerosis ([@B66]). Activation of LXRs has also been studied to treat diabetes. In an *in vitro* human hyperinsulinemia-induced insulin resistance model, activation of LXRs restores insulin sensitivity and decreases inflammatory phenotype. In such a model, addition of T0901317 restores insulin-stimulated glucose up-take, fatty acid synthase expression and counteracts metabolic disorder by decreasing secretion of the pro-inflammatory cytokine IL6 ([@B67]). Due to their ability to counteract lipotoxicity and their putative positive action on bone formation via decreased adipocyte/osteoclast differentiation and favoring osteoblast differentiation ([@B36]--[@B38]), LXRs agonists appear to be hopeful treatments for bone diseases associated with lipid metabolic disorders like ON and OP. Unfortunately artificial LXRs ligands like T0901317 or GW3965 increase serum triglyceride levels and exacerbate steatosis ([@B68]). Use of a selective LXRβ agonist could eventually maintain the beneficial effects as the triggering of SCD1 expression and the anti-inflammatory effect and suppress the impact on hepatic lipogenesis \[for review ([@B69])\]. Another strategy proposed to avoid deleterious effects on liver is the use of tissue-selective drugs carrier ([@B69]). Instead of increasing SCD1 expression via LXRs activation, it would also be conceivable to increase lifespan of the protein by inhibiting the proteasome or by stabilizing the protein through phosphorylation of Y55 ([@B70], [@B71]).

In conclusion, our work demonstrates the essential role of SCD1 as a protective agent against lipotoxicity in bone marrow hMSC. Of interest, a recent study shows modification of SCD1 methylation at the menopausal age ([@B72]). Hypermethylation may impact enzyme expression and therefore, activity, and it is well-known that menopausal women are frequently affected by osteoporosis.

Our work also highlights the importance of maintaining a low intracellular SFA/MUFA ratio to preserve cell viability and validates our hypothesis that the SFA/MUFA ratio rather than Palm accumulation is responsible for cell death. This proposal is further supported by the work of Li et al., showing by NMR spectroscopy studies that bone marrow adipose tissue of ON patients is enriched in SFA and depleted of MUFA, leading to an increase of the SFA/MUFA ratio, when compared to controls subjects. Moreover, they correlated a high SFA/MUFA ratio with a lowest bone mineral density ([@B73]). In this work we performed *in vitro* studies on primary cultures of hMSC. Further *in vivo* studies, using animal models of OP and ON, are needed to better understand the physiological roles of SCD1 and LXRs activation in bone remodeling.

Altogether, our observations support future investigations for the use of LXRs agonists as potential therapeutic tools for bone diseases associated with lipid metabolism dysfunction.
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